AZN/MRK: this caught me by surprise. I guess it gives MRK a little more diversification in their oncology portfolio, and gives AZN a chance to hitch to what's becoming the leading PD-1 esp after MYSTIC failure? Seems like a better deal for AZN than for MRK but maybe I'm missing something...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.